Presentations, Webcasts & Media
Displaying 1 to 2 of 2 files.
Media and News
2011 President's Letter To Shareholders (87.5 KiB) - added April 26, 2012
The Wall Street Transcript - Interview with Robert B Jones (351.1 KiB) - added November 23, 2011
Reprinted from November 14, 2011 issue of The Wall Street Transcript.
Webcasts
Acura Pharmaceuticals First Quarter 2012 Financial Results Conference Call
Wednesday, May 2, 2012 8:30 AM EDT
Presenters: Bob Jones, Chief Executive Officer & Peter Clemens, Chief Financial Officer
Click here to access the webcast.
You may also access the live call by dialing (888) 857-6929 (U.S. and Canada), or (719) 457-2658 (international). The participant passcode is 5534513. A replay of the conference call will be available until May 16, 2012 by clicking the above link or by dialing (888) 203-1112 (U.S. and Canada), or (719) 457-0820 (International). The replay participant passcode is 5534513.
Needham Healthcare Conference
Tuesday, April 3, 2012 3:20 PM EDT
New York Palace Hotel
New York, NY
Presenter: Bob Jones, Chief Executive Officer
Click here to access the webcast. An archived version of the presentation will be available for 30 days after the event.
Acura Pharmaceuticals Fourth Quarter and Fiscal Year 2011 Financial Results Call
Tuesday, March 6, 2012 8:30 AM EST
Presenters: Bob Jones, Chief Executive Officer & Peter Clemens, Chief Financial Officer
Click here to access the webcast.
You may also access the live call by dialing (888) 297-0360 (U.S. and Canada), or (719) 325-2352 (international). The participant passcode is 8695304. A replay of the telecast will be available until March 20, 2012 by clicking the above link.
BioCentury Publications, Inc. NewsMakers in the Biotech Industry Conference
Millennium Broadway Hotel
New York, NY
Friday, October 21, 2011 3:00 PM EDT
Presenter: Bob Jones, Chief Executive Officer
To listen to the audio webcast: Click Here. A replay of the webcast will be available for 30 days after the event.
Displaying 1 to 4 of 4 files.
Presentations
BE Study AP-ADD-100 (769.0 KiB) - added October 19, 2011
Bioequivalence of Immediate-Release Oxycodone With Aversion® Technology (IRO-A), IRO-A With Niacin, and a Commercially Available Oxycodone.
Study Purpose: To evaluate bioequivalence by comparing the pharmacokinetic (PK) characteristics of IRO-A with those of another branded, commercially available immediate-release oxycodone HCl (IRO) (Roxicodone®, Xanodyne Pharmaceuticals, Inc., Newport, KY, USA), and IRO-A with niacin.
Phase III Study AP-ADF-105 (687.8 KiB) - added May 7, 2009
Acurox® Tablets (Oxycodone HCL/Niacin) for the Treatment of Acute, Moderate to Severe Pain Following Bunionectomy Surgery in Adult Patients
Study Purpose: Evaluate safety and efficacy in relief of moderate to severe pain
Phase II Study AP-ADF-111 (962.3 KiB) - added April 30, 2009
A Phase II, Single-Center, Randomized, Double-Blind Assessment of the Subjective Effectes of Acurox® (Oxycodone HCL/Niacin) Tablets in Volunteers With a History of Opioid Abuse
Study Purpose: Evaluate abuse liability of oxycodone HCl/niacin versus oxycodone HCl alone
Phase II Study AP-ADF-102 (280.5 KiB) - added April 21, 2009
Evaluate for Flushing, Safety & Tolerability of Niacin (N) in Combination with 40mg of Oxycodone (O)
Study Purpose: Evaluate relative dislike of oxycodone HCl/niacin versus oxycodone HCl alone
